



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
SODIUM, CALCIUM, MAG, POT OXYBATE	XYWAV	46743		GPI-10 (6245990420)	

**GUIDELINES FOR USE**

**INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)**

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?

If yes, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

If no, continue to #2.

2. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and the diagnosis is confirmed by **ALL** of the following criteria?

- The patient does not have cataplexy
- The patient has a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram is 15 minutes or less
- The patient has 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy in association with a sleep log
- The patient has had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND the patient has experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months

If yes, continue to #3.

If no, continue to #4.

3. Does the patient meet **ALL** of the following criteria?

- The patient is 18 years of age or older
- Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
- The patient had a trial and failure of or contraindication to armodafinil OR modafinil

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**

If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

INITIAL CRITERIA (CONTINUED)

4. Does the patient have a diagnosis of cataplexy in narcolepsy and meet **ALL** of the following criteria?
- The patient is 7 years of age or older
  - Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
  - The patient has tried TWO of the following: venlafaxine, fluoxetine, or a TCA (e.g., amitriptyline, clomipramine, imipramine)

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, continue to #5.

5. Does the patient have a diagnosis of excessive daytime sleepiness (EDS) in narcolepsy and the narcolepsy diagnosis is confirmed by **ONE** of the following criteria?
- The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND two or more early-onset REM sleep periods (SOREMPs)
  - The patient has a Multiple Sleep Latency Test (MSLT) showing both a mean sleep latency of 8 minutes or less AND one or more early-onset REM sleep periods (SOREMPs) AND additionally one early-onset SOREMP (within approx. 15 minutes or less) on a polysomnography the night preceding the MSLT, with the polysomnography has ruled out non-narcolepsy causes of EDS  
**[Note to pharmacist:** Multiple Sleep Latency Test (MSLT) is a guideline-supported instrument for assessing the severity and likelihood of narcolepsy, which consists of five 20-minute nap periods spread throughout a single test day at 2-hour intervals]
  - The patient has low Orexin/Hypocretin levels on CSF assay

If yes, continue to #6.  
If no, do not approve.

**DENIAL TEXT:** See the initial denial text at the end of the guideline.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

INITIAL CRITERIA (CONTINUED)

6. Does the patient meet **ALL** of the following criteria?

- The patient is 7 years of age or older
- Therapy is prescribed by or in consultation with a neurologist, psychiatrist, or specialist in sleep medicine
- The patient has EDS persisting for 3 months or more and an Epworth Sleepiness Scale (ESS) score greater than 10
- The patient meets ONE of the following:
  - The patient is 7 to 17 years of age AND had a trial and failure of or contraindication to one generic stimulant indicated for EDS in narcolepsy (e.g., amphetamine, dextroamphetamine, or methylphenidate)
  - The patient is 18 years of age or older AND had a trial and failure of or contraindication to one agent from EACH of the following categories:
    - Generic typical stimulant (e.g., amphetamine sulfate, dextroamphetamine, methylphenidate)
    - Armodafinil OR modafinil

If yes, **approve for 6 months by HICL or GPI-10 with a quantity limit of #18mL per day.**

If no, do not approve.

**INITIAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav)** requires the following rule(s) be met for approval:

A. You have ONE of the following diagnoses:

1. Idiopathic hypersomnia (IH: a type of sleep disorder)
2. Cataplexy in narcolepsy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
3. Excessive daytime sleepiness (EDS) in narcolepsy (a type of sleep disorder)

B. You are not concurrently on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]

***(Initial denial text continued on next page)***

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES**

**SODIUM/CALCIUM/MAG/POT OXYBATE**

**INITIAL CRITERIA (CONTINUED)**

**C. If you have idiopathic hypersomnia, approval also requires:**

1. You are 18 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. Your diagnosis is confirmed by ALL of the following:
  - a. You do not have cataplexy (sudden and uncontrollable muscle weakness or paralysis associated with a sleep disorder)
  - b. You have a Multiple Sleep Latency Test (MSLT) showing less than 2 sleep-onset REM sleep periods (SOREMP) OR no SOREMPs if REM sleep latency on polysomnogram (type of sleep test) is 15 minutes or less
  - c. You have 1 or more MSLT mean sleep latency of 8 minutes or less, OR total 24-hour sleep is 660 minutes or more on 24-hour polysomnography or by wrist actigraphy (device that monitors movement) in association with a sleep log
  - d. You have had insufficient sleep syndrome ruled out, AND there is no better explanation by another sleep/medical/psychiatric disorder or use of drugs/medications, AND you have experienced daily periods of irrepressible need to sleep or daytime lapses into sleep for at least 3 months
4. You tried and failed or have a contraindication (harmful for) to armodafinil OR modafinil

**D. If you have cataplexy in narcolepsy, approval also requires:**

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have tried TWO of the following: venlafaxine, fluoxetine, or tricyclic anti-depressants (such as amitriptyline, clomipramine, imipramine)

***(Initial denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

INITIAL CRITERIA (CONTINUED)

E. If you have excessive daytime sleepiness in narcolepsy, approval also requires:

1. You are 7 years of age or older
2. Therapy is prescribed by or in consultation with a neurologist (nerve doctor), psychiatrist (mental health doctor), or specialist in sleep medicine
3. You have EDS persisting for 3 or more months and an Epworth Sleepiness Scale (tool to measure your sleepiness) score of more than 10
4. Your diagnosis of narcolepsy is confirmed by ONE of the following:
  - a. A Multiple Sleep Latency Test showing a both an average sleep latency of 8 minutes or less AND 2 or more early-onset rapid eye movement (REM) sleep test periods
  - b. A Multiple Sleep Latency Test (MSLT) showing both an average sleep latency of 8 minutes or less AND one early-onset rapid eye movement (REM) sleep test period (SOREMP) AND additionally one SOREMP (within approximately 15 minutes) on a polysomnography (type of sleep test) the night preceding the MSLT, with the polysomnography ruling out non-narcolepsy causes of excessive daytime sleepiness
  - c. You have low orexin/hypocretin levels on a cerebrospinal fluid (CSF) assay (test showing you have low levels of a chemical that helps with staying awake)
5. If you are 7 to 17 years old, you tried and failed or have a contraindication (harmful for) to one generic stimulant indicated for EDS in narcolepsy (such as amphetamine, dextroamphetamine, or methylphenidate)
6. If you are 18 years or older, you tried and failed or have a contraindication (harmful for) to one agent from EACH of the following categories:
  - a. Generic typical stimulant (such as amphetamine sulfate, methylphenidate, etc.)
  - b. Armodafinil OR modafinil

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Is the patient concurrently on a sedative hypnotic agent (e.g., Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant])?

If yes, do not approve.

**DENIAL TEXT:** See the renewal denial text at the end of the guideline.

If no, continue to #2.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

RENEWAL CRITERIA (CONTINUED)

2. Does the patient have a diagnosis of narcolepsy and meet **ONE** of the following criteria?
- The patient has demonstrated improvement of cataplexy symptoms compared to baseline
  - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline
  - The patient has demonstrated improvement in sleep latency from baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, continue to #3.

3. Does the patient have a diagnosis of idiopathic hypersomnia (IH) and meet **ONE** of the following criteria?
- The patient has demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
  - The patient has maintained an improvement in Epworth Sleepiness Scale (ESS) scores by at least 25% compared to baseline

If yes, **approve for 12 months by HICL or GPI-10 with a quantity limit of #18mL per day.**  
If no, do not approve.

**RENEWAL DENIAL TEXT: \*Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.**

Our guideline named **SODIUM/CALCIUM/MAG/POT OXYBATE (Xywav)** requires the following rule(s) be met for renewal:

- A. You have **ONE** of the following diagnoses:
1. Narcolepsy (uncontrollable daytime sleepiness)
  2. Idiopathic hypersomnia (IH: a type of sleep disorder)
- B. You are not concurrently (at the same time) on a sedative hypnotic agent (drugs that make you sleepy), such as Lunesta [eszopiclone], Ambien [zolpidem], Sonata [zaleplon], estazolam, Restoril [temazepam], Halcion [triazolam], flurazepam, quazepam, Belsomra [suvorexant]
- C. **If you have narcolepsy, renewal also requires you meet ONE of the following:**
1. You have demonstrated improvement in cataplexy symptoms (sudden and uncontrollable muscle weakness) compared to baseline
  2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline
  3. You have demonstrated improvement in sleep latency (the amount of time it takes you to fall asleep)

***(Renewal denial text continued on next page)***

**CONTINUED ON NEXT PAGE**



STANDARD COMMERCIAL DRUG FORMULARY  
PRIOR AUTHORIZATION GUIDELINES

SODIUM/CALCIUM/MAG/POT OXYBATE

RENEWAL CRITERIA (CONTINUED)

D. If you have idiopathic hypersomnia, renewal also requires you meet ONE of the following:

1. You have demonstrated improvement of idiopathic hypersomnia symptoms compared to baseline
2. You have maintained an improvement in Epworth Sleepiness Scale (tool to measure sleepiness) scores by at least 25% compared to baseline

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Xywav.

REFERENCES

- Xywav [Prescribing Information]. Palo Alto, CA: Jazz Pharmaceuticals, Inc.; October 2022.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 01/01/23

Created: 11/20

Client Approval: 11/22

P&T Approval: 10/22